{"product_id":"atosiban-for-threatened-preterm-birth-the-apostel-8-trial-and-the-steroid-debate-explained","title":"Atosiban for Threatened Preterm Birth: The APOSTEL 8 Trial and the Steroid Debate, Explained","description":"\u003cp\u003e\u003cstrong\u003eAPOSTEL 8\u003c\/strong\u003e, a randomized controlled trial published in The Lancet, tested the labor-stopping drug \u003cstrong\u003eatosiban\u003c\/strong\u003e against placebo in 752 patients with threatened preterm birth between 30 and almost 34 weeks of pregnancy. The drug delayed birth for more than 48 hours in more patients (78% versus 69%), but it did not improve newborn health outcomes. Because nearly all participants (98%) also received antenatal corticosteroids (steroid shots to mature the baby's lungs), two expert letters now question whether the standard steroid regimen still makes sense at these gestational ages. The letters call for studies of reduced or individualized steroid dosing, and the trial authors agree the debate is important.\u003c\/p\u003e\n\n\u003ch1\u003eAtosiban for Threatened Preterm Birth: The APOSTEL 8 Trial and the Steroid Debate, Explained\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the APOSTEL 8 Trial Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: The Main Trial Results\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#question1\"\u003eExpert Question 1: Do Steroids Still Help at 30 to 34 Weeks?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#question2\"\u003eExpert Question 2: Do Twin and Singleton Pregnancies Respond Differently?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#question3\"\u003eExpert Question 3: Could Lower or Fewer Steroid Doses Be Safer?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSteroid Safety: What the Research Shows\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#authors\"\u003eThe Trial Authors' Reply\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What These Letters Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Families\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAtosiban delayed birth beyond 48 hours in 78% versus 69% with placebo, but newborn outcomes were not improved.\u003c\/li\u003e\n\u003cli\u003e98% of APOSTEL 8 participants received at least one steroid dose, making it hard to show added benefit from a full course.\u003c\/li\u003e\n\u003cli\u003eExperts question whether standard steroid dosing still helps at 30 to 34 weeks and call for reduced or individualized dose trials.\u003c\/li\u003e\n\u003cli\u003eTwin and singleton pregnancies may respond differently to atosiban and steroids, but the subgroup difference was not statistically reliable.\u003c\/li\u003e\n\u003cli\u003eA new trial called SNACS is testing whether a reduced steroid course is sufficient after 30 weeks; results are not yet available.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003ePreterm birth means a baby is born before 37 completed weeks of pregnancy. When labor threatens to start early, doctors face two urgent tasks. The first is to try to delay birth, often with a \u003cstrong\u003etocolytic\u003c\/strong\u003e (a drug that temporarily stops contractions). The second is to give the mother \u003cstrong\u003eantenatal corticosteroids\u003c\/strong\u003e (steroid medicines given before birth) so the baby's lungs and other organs mature faster.\u003c\/p\u003e\n\n\u003cp\u003eThe drug at the center of this debate is \u003cstrong\u003eatosiban\u003c\/strong\u003e, a tocolytic that works by blocking oxytocin, the hormone that drives labor contractions. Given as an intravenous infusion, it is used to buy time so that steroids can take effect.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCorticosteroids\u003c\/strong\u003e such as \u003cstrong\u003ebetamethasone\u003c\/strong\u003e are standard care for threatened preterm birth. The current dosing regimens were developed from trials conducted in the 1970s and 1980s. Those trials proved that steroids save lives for very early premature babies.\u003c\/p\u003e\n\n\u003cp\u003eHowever, experts disagree about whether the same \"one-size-fits-all\" regimen still gives meaningful benefit at later gestational ages. Studies show that \u003cstrong\u003epreterm-related morbidity and mortality\u003c\/strong\u003e (newborn illness and death linked to premature birth) decline steeply between 28 and 30 weeks of pregnancy. After 30 weeks, the balance between steroid benefits and steroid risks becomes less clear.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the APOSTEL 8 Trial Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eAPOSTEL 8 was a multicenter, randomized, placebo-controlled trial named after the Dutch research group that ran it. The full scientific citation is: van der Windt LI, Klumper J, Duijnhoven RG, et al., \"Atosiban versus placebo for threatened preterm birth (APOSTEL 8),\" published in \u003cem\u003eThe Lancet\u003c\/em\u003e in 2025.\u003c\/p\u003e\n\n\u003cp\u003eThe trial enrolled \u003cstrong\u003e752 participants\u003c\/strong\u003e who arrived at hospitals with threatened preterm birth between \u003cstrong\u003e30 weeks and 0 days (30+0)\u003c\/strong\u003e and \u003cstrong\u003e33 weeks and 6 days (33+6)\u003c\/strong\u003e of gestation. Each participant was randomly assigned to receive either atosiban or an inactive placebo.\u003c\/p\u003e\n\n\u003cp\u003eResearchers measured three main things. First, whether the pregnancy continued for more than 48 hours. Second, whether the participant completed the planned course of antenatal corticosteroids before delivery. Third, and most important, the health outcomes of the newborns, including illness and death.\u003c\/p\u003e\n\n\u003cp\u003eAround one in five participants in the atosiban group (20%) had a twin pregnancy, compared with 15% in the placebo group. The study followed all babies for outcomes after birth.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: The Main Trial Results\u003c\/h2\u003e\n\n\u003cp\u003eThe trial produced three headline results, all of which are important for patients to understand:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAtosiban delayed birth beyond 48 hours more often than placebo.\u003c\/strong\u003e In the atosiban group, 78% of pregnancies (about 78 in 100) continued for more than 48 hours. In the placebo group, 69% (about 69 in 100) did. This difference is expressed as a \u003cstrong\u003erelative risk (RR)\u003c\/strong\u003e of 1.13, with a \u003cstrong\u003e95% confidence interval (CI)\u003c\/strong\u003e of 1.03 to 1.23. Because the entire confidence interval sits above 1.0, the delay is considered statistically significant. A confidence interval is the range within which the true effect most likely lies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore participants in the atosiban group completed their steroid course.\u003c\/strong\u003e The completion rate was 76% in the atosiban group versus 68% in the placebo group (RR 1.11; 95% CI 1.02–1.22). This makes sense: delaying labor gives the steroids time to work.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNewborn outcomes were no better with atosiban.\u003c\/strong\u003e Despite the extra time gained and the higher rate of completed steroid courses, atosiban did not reduce \u003cstrong\u003eneonatal morbidity and mortality\u003c\/strong\u003e (illness and death among newborns).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOne number explains why the authors were puzzled: \u003cstrong\u003e98% of participants in both groups received at least one dose of antenatal corticosteroids\u003c\/strong\u003e, and nearly all received at least half a course. In other words, almost every baby in the study got some steroid protection before birth.\u003c\/p\u003e\n\n\u003ch2 id=\"question1\"\u003eExpert Question 1: Do Steroids Still Help at 30 to 34 Weeks?\u003c\/h2\u003e\n\n\u003cp\u003eTwo groups of obstetric researchers wrote letters to The Lancet after the APOSTEL 8 results appeared. The first group, led by Lola Loussert (Toulouse, France) and Paul Guerby, with colleagues from Lille, France, and Québec City, Canada, congratulated the trial team. Then they raised a pointed question.\u003c\/p\u003e\n\n\u003cp\u003eIf atosiban helped more women complete their full steroid course, the experts reasoned, then the atosiban group should have had healthier babies. It did not. The two groups had identical newborn outcomes. The most likely explanation, they argue, is that a full course of steroids may not add meaningful benefit beyond 30 weeks of pregnancy.\u003c\/p\u003e\n\n\u003cp\u003eThe letter cites a secondary analysis of a separate trial called \u003cstrong\u003eBETADOSE\u003c\/strong\u003e, which compared a half course of corticosteroids with a full course. For babies born before 32 weeks, the study found \u003cstrong\u003eno difference\u003c\/strong\u003e in survival without severe illness: 66.5% in the half-course group versus 65.8% in the full-course group. The risk difference was only 0.7%, with a 95% CI of −5.6 to +7.1. That confidence interval crosses zero, meaning the result is fully compatible with no difference at all.\u003c\/p\u003e\n\n\u003cp\u003eA second group of experts, led by Ruben Ramirez Zegarra (Basel, Switzerland) with Beatrice Valentini and Tullio Ghi (Rome, Italy), made a similar argument with additional evidence. They pointed out that robust data on steroids given between 30+0 and 33+6 weeks are \"sparse\" (very limited). One large observational study of more than 13,000 infants born between 23 and 32 weeks found no survival or breathing benefit for infants born after 29 weeks. Other randomized trials give inconsistent answers: some show benefits between 30 and 34 weeks, and others show no benefit.\u003c\/p\u003e\n\n\u003cp\u003eThe experts stress that the current steroid regimen rests on trials from the 1970s and 1980s. They ask whether it still offers meaningful benefit at 30 to 34 weeks, or whether reduced or \u003cstrong\u003egestational age-tailored dosing\u003c\/strong\u003e (doses adjusted to the baby's exact week of development) could be both safer and equally effective.\u003c\/p\u003e\n\n\u003ch2 id=\"question2\"\u003eExpert Question 2: Do Twin and Singleton Pregnancies Respond Differently?\u003c\/h2\u003e\n\n\u003cp\u003eThe second concern from the Loussert group focuses on twin pregnancies. In APOSTEL 8, the effect of atosiban appeared to go in opposite directions depending on whether the pregnancy carried one baby or two:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIn twin pregnancies\u003c\/strong\u003e, atosiban was associated with a \u003cstrong\u003erelative risk of 1.70\u003c\/strong\u003e (95% CI 0.64–4.51). A relative risk above 1 means a higher chance of the outcome being measured. However, the confidence interval is very wide and includes 1.0, so this result is not statistically reliable on its own.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIn singleton pregnancies\u003c\/strong\u003e, atosiban was associated with a \u003cstrong\u003erelative risk of 0.75\u003c\/strong\u003e (95% CI 0.46–1.23). A relative risk below 1 means a lower chance of the outcome. Again, the confidence interval crosses 1.0.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eStatistically, the formal test for whether these two effects truly differ — the \u003cstrong\u003einteraction test\u003c\/strong\u003e — was not significant (p=0.14). A p-value above 0.05 means the difference between twins and singletons could easily be due to chance. But the experts caution that subgroup analyses like this often \u003cstrong\u003elack statistical power\u003c\/strong\u003e, meaning the study was not large enough to detect a real difference if one exists.\u003c\/p\u003e\n\n\u003cp\u003eThe two groups were also not strictly similar. Twin pregnancies made up 20% of the atosiban group but only 15% of the placebo group. That imbalance matters because twins have different pregnancy risks than singletons.\u003c\/p\u003e\n\n\u003cp\u003eThere is very little published evidence on atosiban or corticosteroids in twin pregnancies, the letter notes. Twins also handle steroid medicines differently at a chemical level. A 2002 study (Ballabh and colleagues) showed that the \u003cstrong\u003epharmacokinetics\u003c\/strong\u003e (how the body absorbs, distributes, and clears a drug) of betamethasone differ between twin and singleton pregnancies. Combining twin and singleton results into one analysis, the experts warn, may have introduced bias into the study's conclusions.\u003c\/p\u003e\n\n\u003ch2 id=\"question3\"\u003eExpert Question 3: Could Lower or Fewer Steroid Doses Be Safer?\u003c\/h2\u003e\n\n\u003cp\u003eThe Basel and Rome group drew attention to a clue inside the APOSTEL 8 data. Since nearly all babies received at least half a course of steroids and outcomes were good, the trial \"hinted\" that a \u003cstrong\u003epartial course\u003c\/strong\u003e (fewer than the standard two doses) might be safe after 30 weeks.\u003c\/p\u003e\n\n\u003cp\u003eOne major trial has already tried this idea. A non-inferiority study involving \u003cstrong\u003e3,244 participants\u003c\/strong\u003e tested a \u003cstrong\u003esingle dose of 11.4 mg of betamethasone\u003c\/strong\u003e against the standard two-dose regimen. The goal of a non-inferiority trial is to prove that the simpler treatment is \"not worse\" than the standard one. In this case, the single dose \u003cstrong\u003efailed to show non-inferiority\u003c\/strong\u003e, meaning researchers could not prove that one dose was as good as two. The experts note, however, that the trial had methodological limitations, especially in how outcomes were chosen and measured.\u003c\/p\u003e\n\n\u003cp\u003eA new trial called \u003cstrong\u003eSNACS (NCT05114096)\u003c\/strong\u003e is currently running. It is expected to provide additional evidence on whether a reduced course of antenatal corticosteroids is sufficient, particularly for the 30-to-34-week window.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSteroid Safety: What the Research Shows\u003c\/h2\u003e\n\n\u003cp\u003eThe letters emphasize that concerns about steroid safety are not new. The risks of antenatal corticosteroids appear to be \u003cstrong\u003edose-dependent\u003c\/strong\u003e, meaning higher or more frequent doses bring greater risk. Repeated courses of steroids have been linked to increased short-term and long-term adverse outcomes in children.\u003c\/p\u003e\n\n\u003cp\u003eThe evidence cited includes several distinct findings:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnimal studies\u003c\/strong\u003e found that steroid exposure caused \u003cstrong\u003edelayed fetal brain growth\u003c\/strong\u003e and \u003cstrong\u003eimpaired cortical development\u003c\/strong\u003e (slower development of the brain's outer layer, which handles thinking, language, and sensation).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHuman cohort studies\u003c\/strong\u003e have reported higher rates of \u003cstrong\u003emental and behavioral disorders\u003c\/strong\u003e in children who were born preterm and exposed to antenatal corticosteroids before birth.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eA meta-analysis of over 1.25 million children\u003c\/strong\u003e found elevated risks of mental and behavioral disorders not only in preterm infants, but also in \u003cstrong\u003elate-preterm and term infants\u003c\/strong\u003e (babies born closer to or at full term) who had been exposed to antenatal corticosteroids.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers behind these letters are not arguing that steroids are useless. They are arguing that the risk-benefit calculation may shift after 30 weeks, when a baby's baseline risk of severe complications is already much lower than at 24 to 28 weeks.\u003c\/p\u003e\n\n\u003ch2 id=\"authors\"\u003eThe Trial Authors' Reply\u003c\/h2\u003e\n\n\u003cp\u003eLarissa I. van der Windt and colleagues, the APOSTEL 8 trial team, published a brief reply alongside the letters. They thanked both groups for their \"thoughtful responses\" to the study. They agreed that both correspondences raise important questions about the \u003cstrong\u003estandard regimen of antenatal corticosteroids\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eIn scientific publishing, an authors' reply that concedes the importance of the critique is significant. It signals that even the trial team recognizes the need for further research on steroid dosing, timing, and the specific needs of the 30-to-34-week gestational window.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor a pregnant person experiencing threatened preterm birth between 30 and 34 weeks, these letters do not change current medical practice overnight. The APOSTEL 8 trial's core finding stands: atosiban delays birth but does not, by itself, improve newborn outcomes. Steroids remain standard care because their benefits are well established for early preterm birth.\u003c\/p\u003e\n\n\u003cp\u003eThe deeper implication is that the medical community is now openly questioning whether the \u003cstrong\u003esame steroid dose should be used for every pregnancy between 24 and 34 weeks\u003c\/strong\u003e. The correspondents call for a shift toward \u003cstrong\u003emore personalized approaches\u003c\/strong\u003e — for example, reduced or individualized dosing for babies at 30+0 to 33+6 weeks, who start with a lower risk of severe complications than babies born at 24 to 28 weeks.\u003c\/p\u003e\n\n\u003cp\u003eFor patients, this means two things. First, the care you receive today is based on the best current evidence, which still supports steroids for threatened preterm birth. Second, the scientific debate is moving toward tailoring treatment to each pregnancy. That includes paying closer attention to whether the pregnancy involves twins, what the mother's blood levels of the drug look like, and exactly how many weeks pregnant the patient is.\u003c\/p\u003e\n\n\u003cp\u003eThe call for urgent research applies to both atosiban and corticosteroids. The experts specifically note there is an urgent need for well-designed trials evaluating \u003cstrong\u003ealternative regimens of antenatal corticosteroids\u003c\/strong\u003e in the 30-to-34-week window, and for better data on twins.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What These Letters Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to recognize what this article is and is not. The APOSTEL 8 trial itself was a well-designed randomized controlled trial, the gold standard for medical evidence. The letters that follow, however, are expert opinions based on secondary analyses and reviews of earlier studies. They are hypothesis-generating, not definitive.\u003c\/p\u003e\n\n\u003cp\u003eThe subgroup finding in twin pregnancies, for example, had a non-significant interaction test (p=0.14). That means the apparent difference between twins and singletons could be a statistical fluke. The experts acknowledge this limitation directly, noting that such analyses often lack power. The baseline imbalance between groups (20% twins in the atosiban group versus 15% in the placebo group) further weakens any subgroup conclusion.\u003c\/p\u003e\n\n\u003cp\u003eThe observational studies cited for steroid risks cannot prove that steroids caused the mental and behavioral disorders seen in children. Confounding factors — such as the reason the mother needed steroids in the first place — could explain part of the association. The animal studies, while concerning, do not always translate directly to humans.\u003c\/p\u003e\n\n\u003cp\u003eFinally, the single-dose betamethasone trial failed to prove non-inferiority, which means we do not currently know whether a reduced dose is safe enough to recommend. The ongoing SNACS trial may provide answers, but results are not yet available.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Families\u003c\/h2\u003e\n\n\u003cp\u003eIf you or someone you love is facing threatened preterm birth, here is what you should know and ask:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not refuse corticosteroids based on this debate.\u003c\/strong\u003e The proven benefit of steroids for babies born before 34 weeks remains the medical standard. The question is about optimal dosing, not about whether steroids have value.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk your obstetrics team whether your situation is singleton or multifetal.\u003c\/strong\u003e The APOSTEL 8 analysis suggests that twin and singleton pregnancies may respond differently to both atosiban and corticosteroids, although this remains unproven. If you are carrying twins, ask specifically how the evidence applies to you.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about gestational age.\u003c\/strong\u003e If you are at 30+0 to 33+6 weeks, the balance of benefits and risks may differ from someone at 24 to 28 weeks. Your care team can explain why they recommend a full, half, or tailored steroid course for your exact week of pregnancy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about tocolysis.\u003c\/strong\u003e Atosiban can delay birth for more than 48 hours, but the APOSTEL 8 trial found no improvement in newborn outcomes. Understand that the purpose of a tocolytic is to provide a window for steroids and for transfer to a hospital with a neonatal intensive care unit (NICU), if needed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about long-term follow-up.\u003c\/strong\u003e Researchers are still investigating the long-term effects of both atosiban and corticosteroids on child development. If your baby is born preterm, ask your pediatrician about appropriate developmental monitoring.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay informed about research updates.\u003c\/strong\u003e The SNACS trial (NCT05114096) and other studies now underway will help clarify whether reduced steroid dosing is safe after 30 weeks. This is an actively evolving area of obstetrics.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIn the meantime, the central message for patients is this: the standard treatments for threatened preterm birth are being carefully re-examined by experts. That re-examination is a sign of a healthy, self-correcting medical field — and it is precisely why evidence-based care continues to improve for mothers and babies.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is atosiban and why is it used?\u003c\/h3\u003e\n\u003cp\u003eAtosiban is a labor-stopping drug given by intravenous infusion. It blocks oxytocin, the hormone that drives contractions. In threatened preterm birth, doctors use it to delay delivery for more than 48 hours. This delay buys time for steroid medicines to mature the baby's lungs before birth.\u003c\/p\u003e\n\u003ch3\u003eDoes atosiban improve the baby's health?\u003c\/h3\u003e\n\u003cp\u003eIn the APOSTEL 8 trial of 752 patients, atosiban delayed birth beyond 48 hours in more patients than placebo, but newborn illness and death rates were the same in both groups. Extra time did not lead to better newborn outcomes. Almost all participants received at least one dose of steroid shots.\u003c\/p\u003e\n\u003ch3\u003eWhat is the debate about steroids at 30 to 34 weeks?\u003c\/h3\u003e\n\u003cp\u003eExperts question whether the standard full course of steroid shots still helps babies born after 30 weeks. A full course may not add meaningful benefit beyond what at least half a course already provides. They call for research on reduced or individualized steroid dosing for this later preterm window.\u003c\/p\u003e\n\u003ch3\u003eDo twin and singleton pregnancies respond differently?\u003c\/h3\u003e\n\u003cp\u003eIn APOSTEL 8, twin pregnancies were 20% of the atosiban group and 15% of the placebo group. Atosiban's effect on newborns appeared different for twins compared to singletons, but the difference could have been due to chance. The study was not large enough to give a reliable answer.\u003c\/p\u003e\n\u003ch3\u003eCould a lower steroid dose be safer?\u003c\/h3\u003e\n\u003cp\u003eSome experts think a partial course of steroids might be safe after 30 weeks because almost all APOSTEL 8 babies received at least half a course and had good outcomes. One large trial could not prove one dose was as good as two. A new trial called SNACS is studying reduced dosing now.\u003c\/p\u003e\n\u003ch3\u003eWhat are the risks of antenatal corticosteroids?\u003c\/h3\u003e\n\u003cp\u003eThe risks appear to increase with higher or more frequent doses. Repeated steroid courses have been linked to delayed fetal brain growth in animals and higher rates of mental and behavioral disorders in children from a large meta-analysis. However, these studies cannot prove that steroids caused the disorders.\u003c\/p\u003e\n\u003ch3\u003eShould I refuse corticosteroids based on this debate?\u003c\/h3\u003e\n\u003cp\u003eNo. The proven benefit of steroids for babies born before 34 weeks remains the medical standard. The debate is about optimal dosing, not about whether steroids have value. Your care team will recommend a course tailored to your exact week of pregnancy and whether you are carrying twins.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion about receiving corticosteroids and atosiban for threatened preterm birth between 30 and 34 weeks?\u003c\/h3\u003e\n\u003cp\u003eIn APOSTEL 8, atosiban delayed birth beyond 48 hours more often than placebo (78% vs 69%), but newborn outcomes were no better. Nearly all participants received steroids, and experts have questioned whether the standard full steroid course adds meaningful benefit after 30 weeks, calling for research on reduced or individualized dosing. If you are 30 to 34 weeks pregnant or carrying twins, a second opinion can help clarify whether the recommended steroid and tocolytic regimen fits your specific situation. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published as correspondence in \u003cem\u003eThe Lancet\u003c\/em\u003e, Volume 406, September 27, 2025, pages 1338–1339.\u003c\/p\u003e\n\n\u003cp\u003eThe original correspondence includes:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOriginal trial:\u003c\/strong\u003e van der Windt LI, Klumper J, Duijnhoven RG, et al. Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial. \u003cem\u003eLancet\u003c\/em\u003e 2025; 405: 1004–13.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLetter 1:\u003c\/strong\u003e Loussert L, Garabedian C, Dupuis N, Bujold E, Guerby P. Atosiban for threatened preterm birth: the APOSTEL 8 trial. Departments of Obstetrics in Toulouse and Lille, France, and Québec City, Canada.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLetter 2:\u003c\/strong\u003e Ramirez Zegarra R, Valentini B, Ghi T. Correspondence from the University Hospital Basel, Switzerland, and Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAuthors' reply:\u003c\/strong\u003e van der Windt LI and colleagues, the APOSTEL 8 trial investigators.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe letters cite numerous supporting studies, including the BETADOSE trial analysis (Baud O, et al., \u003cem\u003eAm J Obstet Gynecol\u003c\/em\u003e 2024), a half-dose versus full-dose betamethasone trial (Schmitz T, et al., \u003cem\u003eLancet\u003c\/em\u003e 2022), a cohort study of over 13,000 infants (Manktelow BN, et al., 2010), a Cochrane systematic review (McGoldrick E, et al., 2020), long-term outcome research after repeat steroid doses (Wapner RJ, et al., \u003cem\u003eN Engl J Med\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576748916892,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/ar\/products\/atosiban-for-threatened-preterm-birth-the-apostel-8-trial-and-the-steroid-debate-explained","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}